Ruth Coll
About
Ruth Coll is a scholar working on Genetics, Surgery and Pathology and Forensic Medicine.
According to data from OpenAlex, Ruth Coll has authored 23 papers receiving a total of 376 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Genetics, 7 papers in Surgery and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Ruth Coll's work include Mesenchymal stem cell research (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Osteoarthritis Treatment and Mechanisms (3 papers). Ruth Coll is often cited by papers focused on Mesenchymal stem cell research (8 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers) and Osteoarthritis Treatment and Mechanisms (3 papers). Ruth Coll collaborates with scholars based in Spain, United Kingdom and Germany. Ruth Coll's co-authors include Joaquim Vives, Margarita Codinach, Joan García‐López, Ramon Lopez Perez, Robert Soler, Marina Huguet, Lluís Orozco, Luciano Rodrı́guez, Joaquim Hernández and Hatice Kumru and has published in prestigious journals such as Circulation, Blood and British Journal of Dermatology.
In The Last Decade
Ruth Coll
21 papers receiving 370 citations
Peers
Ruth Coll
Margarita Codinach Spain
Hiraku Motomura Japan
Qiongfang Cao China
Sung‐Eun Yang United States
Hans-Wilhelm Kaiser Germany
Shreeya Bakshi United States
Jorge Paz Rodríguez United States
Stefan Stich Germany
Yoda Yaghoubi Iran
Naser Aghdami Iran
Citations per year, relative to Ruth Coll Ruth Coll (= 1×)
peers
Margarita Codinach
Countries citing papers authored by Ruth Coll
Since
Specialization
Citations
This map shows the geographic impact of Ruth Coll's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth Coll with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth Coll more than expected).
Fields of papers citing papers by Ruth Coll
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Ruth Coll. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth Coll. The network helps show where Ruth Coll may publish in the future.
Co-authorship network of co-authors of Ruth Coll
This figure shows the co-authorship network connecting the top 25 collaborators of Ruth Coll. A scholar is included among the top collaborators of Ruth Coll based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth Coll. Ruth Coll is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Warren, Richard B., Marjolein de Bruin‐Weller, A. Khemis, et al.. (2025). Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage). British Journal of Dermatology. 193(5). 876–888.
2.
Gold, Linda Stein, Eric L. Simpson, Diamant Thaçi, et al.. (2025). Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From 11 Trials With Over 3000 Patient-Years of Exposure. SKIN The Journal of Cutaneous Medicine. 9(1). s511–s511.
3.
Rodrı́guez, Luciano, et al.. (2024). Treatment of non-hypertrophic pseudoarthrosis of long bones with a Tissue Engineered Product loaded with autologous bone marrow-derived Mesenchymal Stromal Cells: Results from a phase IIa, prospective, randomized, parallel, pilot clinical trial comparing to iliac crest autograft. Injury. 55(7). 111596–111596.
4.
Fuat, Ahmet, Ella Adlen, Mark Monane, et al.. (2024). A polygenic risk score added to a QRISK®2 cardiovascular disease risk calculator demonstrated robust clinical acceptance and clinical utility in the primary care setting. European Journal of Preventive Cardiology. 31(6). 716–722.
5.
Vives, Joaquim, Joaquim Hernández, Hatice Kumru, et al.. (2022). Preclinical Development of a Therapy for Chronic Traumatic Spinal Cord Injury in Rats Using Human Wharton’s Jelly Mesenchymal Stromal Cells: Proof of Concept and Regulatory Compliance. Cells. 11(14). 2153–2153.
6.
Fuat, Ahmet, Ella Adlen, Mark Monane, et al.. (2022). Abstract 10947: A Polygenic Risk Score Added to a QRISK2 Cardiovascular Risk Calculator Demonstrated Robust Clinical Acceptance in the Primary Care Setting. Circulation. 146(Suppl_1).
7.
Barba, Pere, Elisa Roldán, María Suárez‐Lledó, et al.. (2022). Viral-Specific T Cell Therapy for Cytomegalovirus Infection after Stem Cell Transplantation and Generation of a Third-Party T-Cell Donor Registry. Blood. 140(Supplement 1). 10309–10310.
8.
Gastelurrutia, Paloma, Cristina Prat‐Vidal, Joaquim Vives, et al.. (2021). Transitioning From Preclinical Evidence to Advanced Therapy Medicinal Product: A Spanish Experience. Frontiers in Cardiovascular Medicine. 8. 604434–604434.
9.
Coll, Ruth, Miquel Adrover, Joan García‐López, et al.. (2020). Randomized clinical trial: expanded autologous bone marrow mesenchymal cells combined with allogeneic bone tissue, compared with autologous iliac crest graft in lumbar fusion surgery. The Spine Journal. 20(12). 1899–1910.
10.
Albu, Sergiu, Hatice Kumru, Ruth Coll, et al.. (2020). Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 23(2). 146–156.
11.
Rodrı́guez, Luciano, Joaquim Vives, Ruth Coll, et al.. (2020). Cord blood-derived platelet concentrates as starting material for new therapeutic blood components prepared in a public cord blood bank: from product development to clinical application.. Vox Sanguinis. 18(3). 208–216.
12.
Soler, Robert, Lluís Orozco, Marina Huguet, et al.. (2016). Final results of a phase I–II trial using ex vivo expanded autologous Mesenchymal Stromal Cells for the treatment of osteoarthritis of the knee confirming safety and suggesting cartilage regeneration. The Knee. 23(4). 647–654.
13.
Vives, Joaquim, Margarita Codinach, Ruth Coll, et al.. (2015). Development of an advanced cell therapy product indicated for the treatment of gonarthrosis. BMC Proceedings. 9(S9).
14.
Vives, Joaquim, Margarita Codinach, Irene Oliver‐Vila, et al.. (2014). Development of a new advanced theraphy medicinal product for bone regeneration treatment; from bench to bedside. Cytotherapy. 16(4). S103–S103.
15.
Vives, Joaquim, Margarita Codinach, Irene Oliver‐Vila, et al.. (2014). Advanced cell therapy indicated for gonarthrosis treatment: the way to the completed clinical trial. Cytotherapy. 16(4). S103–S104.
16.
Gugliotta, L, Martin Grießhammer, Jean‐Jacques Kiladjian, et al.. (2013). Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Haematologica. 99(4). 679–687.
17.
Besses, Carlos, W. Zeller, Alberto Álvarez‐Larrán, et al.. (2012). Pharmacokinetics and tolerability of anagrelide hydrochloride in young (18 50 years) and elderly (? 65 years) patients with essential thrombocythemia. International Journal of Clinical Pharmacology and Therapeutics. 50(11). 787–796.
18.
Besses, Carlos, Jean‐Jacques Kiladjian, Martin Grießhammer, et al.. (2012). Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Leukemia Research. 37(2). 162–168.
19.
Kiladjian, Jean‐Jacques, Carlos Besses, Martin Grießhammer, et al.. (2012). Efficacy and Safety of Cytoreductive Therapies in Patients with Essential Thrombocythaemia Aged >80 Years: An Interim Analysis of the EXELS Study. Clinical Drug Investigation. 33(1). 55–63.
20.
Coll, Ruth. (1987). Comparative activity of three new fluoroquinolones.. PubMed. 6(2 Suppl). 152–3.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Margarita Codinach Breakdown of academic impact, for papers by Hiraku Motomura Breakdown of academic impact, for papers by Qiongfang Cao Breakdown of academic impact, for papers by Sung‐Eun Yang Breakdown of academic impact, for papers by Hans-Wilhelm Kaiser Breakdown of academic impact, for papers by Shreeya Bakshi Breakdown of academic impact, for papers by Jorge Paz Rodríguez Breakdown of academic impact, for papers by Stefan Stich Breakdown of academic impact, for papers by Yoda Yaghoubi Breakdown of academic impact, for papers by Naser Aghdami